Related Experiment Video

Updated: Apr 12, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.3K

PARP inhibitors and breast cancer: from therapeutic breakthrough to resistance challenge

Weiyun Wang1, Chenghui Cai2, Sisi Qin3

  • 1Guizhou University of Traditional Chinese Medicine, Guiyang, China.

Experimental & Molecular Medicine
|April 10, 2026
PubMed

Insights

Poly(ADP-ribose) polymerase (PARP) inhibitors are vital for treating certain breast cancers. Understanding and overcoming resistance to these drugs is crucial for improving patient outcomes.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Breast cancer is a leading cause of death in women globally.
  • Poly(ADP-ribose) polymerase (PARP) inhibitors offer a key treatment for specific breast cancer types, including triple-negative and HER2-negative metastatic cases with BRCA mutations.
  • Resistance to PARP inhibitors presents a significant clinical hurdle.

Purpose of the Study:

  • To provide a detailed review of PARP inhibitor mechanisms and clinical applications.
  • To explore the mechanisms of primary and acquired resistance to PARP inhibitors.
  • To discuss strategies for overcoming PARP inhibitor resistance.

Main Methods:

  • Literature review of PARP inhibitor mechanisms.
  • Analysis of clinical trial data for PARP inhibitors.
  • Review of studies on resistance mechanisms and therapeutic strategies.

Main Results:

  • PARP inhibitors target DNA repair pathways, showing efficacy in BRCA-mutated cancers.
  • Multiple mechanisms contribute to both primary and acquired resistance.
  • Combinatorial therapies and novel drug development show promise in overcoming resistance.

Conclusions:

  • PARP inhibitors are effective but resistance limits their long-term use.
  • Understanding resistance mechanisms is key to developing effective treatment strategies.
  • Future research should focus on overcoming resistance to maximize the benefit of PARP inhibitors in breast cancer treatment.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.7K
Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K